The global biodefense market size was valued at US$ 16.31 billion in the year 2023 and is estimated to reach a revised size of US$ 32.99 billion by 2033. This market is projected to expand at a CAGR of 7.3% during the analysis period. Increasing demand for vaccines, drugs, and medical devices creates opportunities for companies to expand their businesses and penetrate new markets.
Biological terrorism involves the deliberate release of viruses, bacteria, and other harmful germs capable of spreading epidemics and causing death. It has a detrimental impact on the economy because of the damage it causes to human health and the drain on human resources. Therefore, developed countries undertake a variety of efforts, as well as preventive measures, to strengthen their defense against these attacks.
Various countries maintain a constant supply of vaccines and biothreat detection technology to ensure the safety of their citizens. Government initiatives like this may help to accelerate the growth of the biodefense industry. It is possible to use biological toxins or infectious agents with malicious intentions, such as killing or infecting humans, animals, or the environment or even provoking biological warfare. In addition to living organisms such as bacteria, viruses, fungi, and toxins, several agents are used in bioterrorism.
By deliberately infecting and killing people, these agents can be used to cause social and economic turmoil. As a result of government initiatives, and increased government attention and funding towards biodefense strategies, the biodefense market is fueled by various factors. For example, the Department of Defense is modernizing its approach to develop medical countermeasures to protect warfighters from novel biological agents.
In the years to come, the scope of the biodefense market may be further expanded by increasing private investment. This is due to the occurrence of different viruses such as the flu, the Ebola virus, and the Zika virus.
Some technological advancements have been made in genetic engineering and biotechnology in the past few years. These advancements have enabled innovative approaches to combat these deadly, naturally occurring viruses that can be redesigned to cause additional harm. Moreover, these organisms are readily available, making biodefense an imperative aspect of countries around the world. The use of various biological agents, such as botulism, anthrax, and chemical and nuclear agents, has contributed to severe destruction as a result of bioterrorism.
| Attributes | Details |
|---|---|
| Biodefense Market Value (2023) | US$ 16.31 billion |
| Biodefense Market Expected Value (2033) | US$ 32.99 billion |
| Biodefense Market Projected CAGR (2023 to 2033) | 7.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global biodefense market expanded at 8.1% CAGR over the past 10 years. The market is anticipated to expand at a CAGR of close to 7.3% over the forthcoming decade.
Biodefense markets were positively impacted by the pandemic. As a result of the pandemic, numerous government and non-governmental agencies were required to coordinate their responses nationwide, as catastrophic biological events can result in significant human and economic losses. Since the pandemic promises huge potential for investment and income redistribution, there are many reasons to believe it is an intentional act of bioterrorism.
| Historical CAGR (2016 to 2022) | 8.1% |
|---|---|
| Historical Market Value (2022) | US$ 15.20 billion |
| Forecast CAGR | 7.3% |
Due to the rise of bioterrorism, prominent industry players have incorporated advances in biothreat detection systems. These advances aid in the identification of bacteria and viruses that may be beneficial to market growth during the analysis period. As a result, technological breakthroughs can have a beneficial influence on market growth. To secure the security and safety of the population, technologically sophisticated biothreat detection technologies are necessary, which can help boost the market's growth.
To detect pathogens in nanotechnology, forensics, and biodefense-related drug development, innovative technologies, including gene chips, are widely used. As a means of improving agricultural yields, synthetic biology is also contributing to market growth, as it improves agricultural yields.
It is one of the key factors driving the growth of the market that the threat of terrorism is growing along with an ever-increasing level of tension between nations. It is also contributing to biodefense market growth that governments across several nations are increasing their defense spending to improve both internal and external security.
For example, the United States Department of Defense (DoD) spent US$ 718 billion in FY 2021, with the large category being operation and maintenance at US$ 286 billion. Furthermore, government agencies are developing medical countermeasures for chemical, biological, nuclear, and radiological threats to minimize the adverse effects of these attacks.
The development of novel vaccine technologies, such as vector technology, is expected to drive the growth of the biodefense market as they can provide rapid protection against pathogen attacks. In recent years, vaccines have been developed that can combat a wide variety of bioterrorism chemicals and can induce long-lasting immune responses.
Several countries are experiencing a surge in Ebola and Zika infections, resulting in a race to develop vaccines. The government spends a lot of money on vaccine research and development to make sure it is prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense market have a huge opportunity to expand since governments are always looking for ways to prevent bioterrorism.
Principal Consultant
In terms of products, the market is segmented into anthrax, smallpox, botulism, radiation/nuclear, and others. The anthrax segment held a prominent market share of 28.1% in 2023. Many factors contribute to the growth of the anthrax product segment. Some of these factors include the increase in anthrax outbreaks in humans, favorable government initiatives, and collaboration in research and development in the studied fields.
In July 2022, as reported by the media, 15 cases of cutaneous anthrax were linked to an anthrax outbreak in cattle in Sisak-Moslavina County following heavy rain, according to the European Centre for Disease Prevention and Control (ECDC) Communicable Disease Threat Report. Moreover, in July 2022, the Croatian Ministry of Agriculture issued an order containing measures to prevent the outbreak and spread of anthrax in the affected area. These measures include closures of affected areas, vaccinations of animals, and additional human prevention measures.
One of the most likely potential weapons used in a bioterrorist attack is Bacillus anthracis, a gram-positive bacterium that causes anthrax. Those spores are preferred because they can be easily released into the environment by adding them to food, water, powders, and sprays. The bacterium can persist in the environment for a long time and is easily found in nature (soil, plants, or water). As anthrax bacteria can be easily transmitted from one person to another, NCBI categorizes it as a tier-1 biological agent, which has the potential to cause a massive public health disaster.
In the field of countermeasures, anthrax remains a key focus. It has received a significant amount of funding for vaccine development. Many companies have developed anthrax vaccines, including Bioshield, which has received over US$ 50 billion in funding since the September 11 attacks.
In recent years, many countries have seen a rise in infection cases caused by the Zika virus and Ebola virus. This has prompted many companies to compete to develop vaccines for these viruses. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against two filoviruses, Ebola and Marburg's diseases, currently in phase 3 clinical trials and collaborating with the United States NIAID for the same.
In 2023, North America accounted for 79% of the biodefense market and is expected to exhibit a significant growth rate. As a result of federal funding, technological advancements, and growing awareness, this market is projected to expand significantly in the forecast period. Key players in this region make it easy for the biodefense market to grow in 2023. Increased research and development in the studies field, as well as increasing government initiatives, are the primary growth factors in this market.
During the forthcoming years, the United States Biodefense Market is expected to dominate North America due to the growing importance of biodefense and increasing threats from harmful biological materials. Furthermore, the United States has well-established vaccine production facilities and is one of the region's most developed biodefense markets. Moreover, the United States government implements some initiatives that help them strengthen security against bioterrorism attacks. For example, the government plans a pandemic influenza program and a program to fight infectious diseases.
The regional market forecast may also be influenced by other factors, such as the growing adoption of technologically advanced products and the increasing awareness of biodefense among individuals.
A leadership structure and a comprehensive strategy were established in National Security Presidential Memorandum 14 (NSPM-14) to coordinate all biodefense efforts associated with the U.S. Government. The combination of the strategy and memorandum enabled the annual budget planning process to identify and connect gaps for the first time.
In Germany, biodefense products and services are manufactured and sold to protect against biological threats such as infectious diseases and bioterrorism. It consists of a wide range of products and services, including vaccinations, diagnostic tests, protective equipment, and decontamination systems.
Germany is considered a leading player in the global biodefense market. This is because it has a strong presence of multinational corporations and government institutions involved in research and development, as well as the production and distribution of biodefense products. The government of Germany has also made significant investments in the biodefense sector, which has helped to spur growth and innovation in the market.
Overall, the biodefense market in Germany is expected to continue growing in the coming years. This is driven by factors such as increasing concerns about global pandemics, bioterrorism, and the growing threat of antimicrobial resistance.
During the forecast period, China is expected to expand at the high rate of 8.8% due to surges in Research and development. Growing awareness of biodefense, as well as the threat of harmful biological materials that engender emergencies, can drive growth in the biodefense market.
A combination of this and a sophisticated healthcare infrastructure contributes to China's market position. In addition, China is vigorously expanding its research and development capabilities to meet future biological threats. After the United States, China spends the second highest percentage of its GDP on research and development. These factors are expected to boost China's biodefense industry.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The biodefense market is home to several startups around the world. These startups are focused on developing innovative solutions to protect against biological threats, including infectious diseases and bioterrorism.
Some examples of Startups Operating in the Biodefense Market include:
These startups are working on developing and commercializing cutting-edge technologies and products to address the challenges posed by biological threats. They play an influential role in driving innovation and growth in the biodefense market.
In emerging and economically favorable regions, many of these players are notably collaborating with governments to gain bulk orders and boost sales. Many companies are partnering with each other to develop drugs so that they can introduce their products fast.
Key players operating in the Market:
Recent Developments:
Key players are focusing on novel and innovative approaches for the development of new Biodefenses. The strategy of expansion, new product launches, and approvals, by key manufacturers, are crucial strategies for further strengthening the presence of market players and allowing them to stay ahead of the competition.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ million for Value and MT for Volume |
| Key Regions Covered |
|
| Key Countries Covered | United States, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom, Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Türkiye |
| Key Segments Covered |
|
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The valuation of the biodefense market reaches a notable sum of US$ 16.31 billion in 2023.
The biodefense market is estimated to achieve a valuation of US$ 32.99 billion by 2033.
The biodefense market is poised to witness a 7.3% CAGR through 2033.
Advanced detection technologies stand out as the top trend in the biodefense market.
The anthrax segment is positioned to sustain its preference in the market through 2033, holding a 28.1% share.
1. Executive Summary | Biodefense Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Anthrax Biodefense 5.3.2. Botulism Biodefense 5.3.3. Smallpox Biodefense 5.3.4. Cholera Biodefense 5.3.5. Influenza Biodefense 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033 6.3.1. Hospitals and Clinics 6.3.2. Ambulatory Care Centres 6.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Type 8.2.3. By End-User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Type 8.3.3. By End-User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Type 9.2.3. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By End-User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Type 10.2.3. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By End-User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Type 11.2.3. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By End-User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Type 12.2.3. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By End-User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Type 13.2.3. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By End-User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Type 14.2.3. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By End-User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Type 15.1.2.2. By End-User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Type 15.2.2.2. By End-User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Type 15.3.2.2. By End-User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Type 15.4.2.2. By End-User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Type 15.5.2.2. By End-User 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Type 15.6.2.2. By End-User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Type 15.7.2.2. By End-User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Type 15.8.2.2. By End-User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Type 15.9.2.2. By End-User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Type 15.10.2.2. By End-User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Type 15.11.2.2. By End-User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Type 15.12.2.2. By End-User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Type 15.13.2.2. By End-User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Type 15.14.2.2. By End-User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Type 15.15.2.2. By End-User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Type 15.16.2.2. By End-User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Type 15.17.2.2. By End-User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Type 15.18.2.2. By End-User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Type 15.19.2.2. By End-User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Type 15.20.2.2. By End-User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Type 15.21.2.2. By End-User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Type 16.3.3. By End-User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. XOMA corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Altimmune Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Emergent Biosolutions Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Dynavax Technologies Corporation. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. SIGA Technologies. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Elusys Therapeutics Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Ichor Medical Systems. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Dynport Vaccine Company. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Cleveland Biolabs. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Bavarian Nordic. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Ology Bioservices. 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Alnylam Pharmaceuticals Inc 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Biodefense Market
